Kilitch Drugs (India) Ltd

Kilitch Drugs (India) Ltd

₹ 350 6.72%
08 Oct 9:26 a.m.
About

Incorporated in 1978, Kilitch Drugs Ltd is engaged in the operation and management of Pharmaceutical Products[1]

Key Points

Business Overview:[1]
KDL is a pharmaceutical company engaged in developing, manufacturing, marketing, and exporting various Pharmaceutical Formulations in dosage forms like Solid, Liquid, and Parental.

  • Market Cap 563 Cr.
  • Current Price 350
  • High / Low 470 / 248
  • Stock P/E 55.3
  • Book Value 110
  • Dividend Yield 0.00 %
  • ROCE 12.8 %
  • ROE 7.83 %
  • Face Value 10.0

Pros

  • Company has delivered good profit growth of 35.1% CAGR over last 5 years

Cons

  • Stock is trading at 3.00 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 5.90% over last 3 years.
  • Company's cost of borrowing seems high
  • Working capital days have increased from 61.3 days to 105 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024
19.62 23.57 34.43 36.61 33.45 30.70 29.97 45.48 36.56 41.20 31.79 44.82 33.45
18.71 19.92 33.66 31.57 30.03 26.75 25.99 39.26 30.38 32.58 29.51 37.74 31.79
Operating Profit 0.91 3.65 0.77 5.04 3.42 3.95 3.98 6.22 6.18 8.62 2.28 7.08 1.66
OPM % 4.64% 15.49% 2.24% 13.77% 10.22% 12.87% 13.28% 13.68% 16.90% 20.92% 7.17% 15.80% 4.96%
1.05 0.17 1.31 0.38 0.97 0.24 0.69 1.02 0.56 0.49 2.96 0.47 2.57
Interest 0.13 0.12 0.24 0.71 0.67 1.75 1.29 1.21 1.50 1.51 1.60 1.32 1.73
Depreciation 0.44 0.70 0.20 1.13 0.82 0.89 0.93 0.91 0.71 0.82 0.81 0.93 0.85
Profit before tax 1.39 3.00 1.64 3.58 2.90 1.55 2.45 5.12 4.53 6.78 2.83 5.30 1.65
Tax % 47.48% 14.00% 62.80% 36.03% 40.00% -25.16% 30.61% 43.16% 32.67% 24.93% 38.16% 30.57% 93.33%
0.72 2.58 0.61 2.30 1.74 1.94 1.71 2.90 3.06 5.09 1.74 3.68 0.11
EPS in Rs 0.76 1.39 0.72 1.86 1.34 1.56 1.52 2.28 2.16 2.95 1.81 2.23 0.83
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2012 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
146 108 19 21 27 51 82 53 68 114 140 154 151
124 95 21 25 28 45 75 53 63 104 122 130 132
Operating Profit 22 13 -2 -4 -1 6 7 0 5 10 18 24 20
OPM % 15% 12% -9% -19% -2% 11% 9% 1% 8% 9% 13% 16% 13%
0 92 3 2 1 3 4 4 3 3 3 4 6
Interest 4 3 0 0 0 0 1 1 1 1 5 6 6
Depreciation 6 5 2 10 10 2 2 2 2 2 4 3 3
Profit before tax 13 97 -1 -12 -9 6 9 2 5 10 12 19 17
Tax % 20% 22% -70% -4% -5% 16% 55% 48% 27% 35% 31% 30%
10 76 -0 -11 -9 5 4 1 4 6 8 14 11
EPS in Rs 7.93 57.67 -0.22 -8.46 -6.72 3.75 2.49 0.54 2.43 4.73 6.71 9.08 7.82
Dividend Payout % 13% 52% 0% 0% 0% 13% 20% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 13%
3 Years: 31%
TTM: 6%
Compounded Profit Growth
10 Years: %
5 Years: 35%
3 Years: 62%
TTM: 6%
Stock Price CAGR
10 Years: 29%
5 Years: 23%
3 Years: 24%
1 Year: 25%
Return on Equity
10 Years: %
5 Years: 4%
3 Years: 6%
Last Year: 8%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2012 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 13 13 13 13 13 14 15 15 15 16 16 16
Reserves 71 101 107 95 88 98 106 103 112 121 131 160
16 9 0 0 1 1 9 13 15 20 22 32
53 54 7 8 11 15 13 12 61 53 51 32
Total Liabilities 153 177 127 117 113 128 144 143 203 210 220 240
42 9 9 42 33 33 32 32 30 65 64 62
CWIP 43 0 0 0 1 3 20 30 65 3 4 6
Investments 0 138 72 49 53 56 53 52 60 71 62 72
68 30 46 25 26 35 38 30 47 71 90 100
Total Assets 153 177 127 117 113 128 144 143 203 210 220 240

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2012 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
22 -29 -8 17 1 1 0 4 46 6 3 -0
-24 41 -31 -20 -2 -4 -14 -10 -38 -15 8 -10
7 -9 -0 0 -0 6 17 1 2 7 -1 9
Net Cash Flow 6 2 -39 -2 -0 2 3 -5 10 -2 10 -1

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2012 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 97 51 243 286 196 148 86 109 122 132 142 149
Inventory Days 62 12 124 110 84 39 36 70 35 28 10 18
Days Payable 37 19 124 154 184 108 33 89 525 239 200 118
Cash Conversion Cycle 121 44 243 241 96 79 89 89 -367 -79 -48 50
Working Capital Days 19 -114 197 237 124 100 79 108 -144 25 54 105
ROCE % 15% 8% -10% -9% 5% 6% 1% 3% 6% 10% 13%

Shareholding Pattern

Numbers in percentages

4 Recently
Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
68.33% 68.25% 68.25% 68.25% 68.24% 68.24% 68.24% 68.24% 69.23% 69.23% 69.23% 69.23%
0.00% 0.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
31.67% 31.73% 31.75% 31.75% 31.75% 31.75% 31.75% 31.76% 30.78% 30.76% 30.77% 30.77%
No. of Shareholders 8,7409,1299,1339,2099,3809,4359,5229,5739,0029,0629,5259,620

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents